Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.
Several other analysts have also recently weighed in on the company. Weiss Ratings raised Rocket One Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. D. Boral Capital reissued a “buy” rating and set a $5.00 price target on shares of Rocket One Inc. Common Stock in a research note on Wednesday, March 25th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Rocket One Inc. Common Stock presently has a consensus rating of “Hold” and an average target price of $5.00.
Get Our Latest Analysis on RKTO
Rocket One Inc. Common Stock Price Performance
Rocket One Inc. Common Stock (NASDAQ:RKTO – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03).
Institutional Investors Weigh In On Rocket One Inc. Common Stock
A number of institutional investors have recently made changes to their positions in RKTO. Geode Capital Management LLC increased its holdings in Rocket One Inc. Common Stock by 8.0% in the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after purchasing an additional 9,071 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Rocket One Inc. Common Stock during the 3rd quarter worth about $184,000. Citadel Advisors LLC acquired a new position in shares of Rocket One Inc. Common Stock during the 3rd quarter worth about $232,000. Lido Advisors LLC acquired a new position in shares of Rocket One Inc. Common Stock during the 3rd quarter worth about $32,000. Finally, Kestra Private Wealth Services LLC bought a new stake in shares of Rocket One Inc. Common Stock in the 3rd quarter valued at about $51,000. 7.08% of the stock is owned by institutional investors and hedge funds.
About Rocket One Inc. Common Stock
Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.
Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.
Featured Articles
- Five stocks we like better than Rocket One Inc. Common Stock
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
- Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
- 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Receive News & Ratings for Rocket One Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket One Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
